PERSPECTIVES ON PROPHYLACTIC FACTOR REPLACEMENT FROM ADULT PATIENTS WITH MODERATE AND SEVERE HEMOPHILIA

被引：0
|
作者：
Petrucci, Jessica [1 ]
Floros, Georgina [1 ]
Longmore, Avery [1 ,2 ]
Teitel, Jerome [1 ,2 ]
Sholzberg, Michelle [1 ,2 ,3 ]
机构：
[1] St Michaels Hosp, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Li Ka Shing Knowledge Inst, Toronto, ON, Canada
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2018年 / 93卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E53 / E53
页数：1
相关论文
共 50 条
  • [21] Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B
    Andreeva, Tatiana
    Zorenko, Vladimir Yu.
    Davydkin, Igor
    Konstantinova, Valeria
    Zalepukhina, Olga
    Klimova, Nina
    Mishin, Georgy
    Kurtov, Igor
    Shamina, Maria
    Fatenkova, Elena
    Gusyakova, Olga
    Shuster, Alexandr
    Kudlay, Dmitry
    Lukyanov, Sergey
    Borozinets, Anton
    Nikitin, Eugene
    Klykova, Ekaterina
    BLOOD, 2015, 126 (23)
  • [22] TREATMENT PREFERENCE OF MODERATE OR SEVERE HEMOPHILIA A PATIENTS IN TAIWAN
    Chiou, S. S.
    Weng, T. F.
    Wang, J. D.
    VALUE IN HEALTH, 2022, 25 (12) : S408 - S408
  • [23] Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy
    Di Brino, Eugenio
    Yan, Songkai
    Tomic, Radovan
    Panebianco, Marco
    Dlotko, Ewa
    Stern, Lee
    Basile, Michele
    Rumi, Filippo
    Cicchetti, Americo
    Marino, Renato
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 554 - 564
  • [24] Personalization of Clotting Factor VIII Replacement Therapy Based on Population Pharmacokinetics in Adult Patients with Severe Hemophilia a Who Frequently Switch Factor VIII Concentrates
    Windyga, Jerzy
    Odnoczko, Edyta
    Stefanska-Windyga, Ewa
    Baran, Beata
    Sikorska, Anna
    Gorska-Kosicka, Magdalena
    Zawilski, Janusz
    Letowska, Magdalena
    BLOOD, 2022, 140 : 8451 - 8452
  • [25] INCIDENCE OF INHIBITORS IN PATIENTS WITH SEVERE AND MODERATE HEMOPHILIA-A TREATED WITH FACTOR-VIII CONCENTRATES
    SCHWARZINGER, I
    PABINGER, I
    KORNINGER, C
    HASCHKE, F
    KUNDI, M
    NIESSNER, H
    LECHNER, K
    AMERICAN JOURNAL OF HEMATOLOGY, 1987, 24 (03) : 241 - 245
  • [26] Laboratory control of replacement therapy in severe hemophilia A patients
    Balandina, A.
    Zapariy, A.
    Polokhov, D. M.
    Yakovleva, V
    Kargaltsev, A.
    Konyashina, N., I
    Polyanskaya, T. U.
    Kopylov, K. G.
    Ataullakhanov, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 926 - 926
  • [27] Prophylactic Treatment with New Recombinant Factor IX Innonafactor (Russia) in Adolescent and Adult Patients with Hemophilia B
    Shiller, Ekaterina
    Petrov, Victor
    Svirin, Pavel
    Vdovin, Vladimir
    Koltunov, Igor
    Bullih, Artyom
    Maschan, Michael A.
    Kudlay, Dmitry
    Klykova, Ekaterina
    BLOOD, 2017, 130
  • [28] Replacement therapy with virus-inactivated clotting factor concentrates in patients with severe hemophilia in Heidelberg
    Zimmermann, R
    Uhle, C
    Huth-Kühne, A
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 : 75 - 78
  • [29] Cost-effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States
    Potnis, Kunal C.
    Viswanathan, Giri
    Bona, Robert D.
    Ito, Satoko
    Kempton, Christine L.
    Pandya, Ankur
    Krumholz, Harlan M.
    Goshua, George
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (09) : E247 - E250
  • [30] The factor VIII treatment history of non-severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEAD-US system
    Alvarez Roman, Maria Teresa
    de la Corte Rodriguez, Hortensia
    Bonanad Boix, Santiago
    Mingot-Castellano, Maria Eva
    Fernandez Mosteirin, Nuria
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (10) : 2638 - 2641
12345